Highlights

  • Second quarter 2026 revenue rose 48% to $64.1 million, driven by a 74% increase in revenue case volume.
  • Gross profit grew 62% to $53.2 million, while the quarterly net loss widened to $15.7 million from $9.2 million.
  • Heartflow held $246.8 million of cash and investments on June 30, 2026, sufficient for at least 12 months, it says.
  • The company disclosed a Department of Justice civil investigative demand and filed a patent lawsuit against Cleerly in April 2026.

Heartflow (NASDAQ:HTFL) shares were trading near their 52-week high at USD 55.94 on October 21, 2026, up 0.63%. The coronary artery disease software company launched its PCI Navigator product in April, sued a competitor over patents that month, and filed its quarterly report for the period ended June 30, 2026 on August 13.

Based in San Francisco, California, Heartflow was incorporated in Delaware in July 2007. It describes itself as a commercial-stage medical technology company that uses artificial intelligence and computational fluid dynamics to build a personalized 3D heart model from a single coronary CT angiogram. It offers FFR CT Analysis, Plaque Analysis, RoadMap Analysis and PCI Navigator, and it expects a fifth product, Plaque Tracker, in 2027. Substantially all revenue comes from pay-per-use fees each time a physician reviews an analysis.

Revenue Up 48% as Case Volume Climbs 74%

Revenue for the three months ended June 30, 2026 was $64.1 million, up from $43.4 million a year earlier. The company said the increase came mainly from the 74% rise in revenue cases, helped by adoption of Plaque Analysis and by expanded reimbursement coverage under CPT code 75577 that took effect January 1, 2026. Average selling prices were lower, reflecting a larger share of cases from clinic and office-based accounts and higher volume rebates. The company reported 84,491 revenue cases in the quarter, versus 48,423 in the second quarter of 2025.

Gross profit rose to $53.2 million from $32.8 million, as cost of revenue grew only 2% to $10.9 million. Spending grew faster. Research and development expenses rose 75% to $26.3 million, largely on higher headcount, and selling, general and administrative expenses rose 42% to $44.8 million. The loss from operations was $17.9 million versus $13.7 million. The GAAP net loss was $15.7 million, or $0.18 per share, compared with $9.2 million, or $1.46 per share, a year earlier, when the share count was far lower before the August 2025 IPO.

For the six months, revenue was $116.7 million, up 45%, and the net loss was $43.1 million, compared with $41.5 million. The first half included a $7.5 million non-cash impairment charge on a Mountain View, California facility. Net cash used in operating activities was $38.7 million.

Balance Sheet, Investigation and Patent Suit

Heartflow had $246.8 million in cash, cash equivalents and investments and an accumulated deficit of $1.1 billion at June 30, 2026. It repaid its term loan in August 2025 and its convertible notes converted at the IPO. Management believes existing resources and expected customer cash will fund operations for at least 12 months, but warned that assumptions could prove wrong and that more capital might be needed.

In October 2025 the company and certain employees received civil investigative demands from the U.S. Department of Justice, Civil Division, tied to an investigation under the federal Anti-Kickback Statute and Civil False Claims Act. The demands seek information on financial and contractual arrangements with providers and on sales and marketing activities. Heartflow is cooperating, cannot say how long it will last or estimate any financial impact, and notes that the outcome could have a material effect on its business.

On April 13, 2026, it sued Cleerly, Inc. in federal court in the Eastern District of Texas, alleging that three Cleerly products infringe six of its patents. It seeks an injunction and damages.

Outlook and Stated Priorities

The quarterly report contains no numerical revenue guidance. Management points to adoption of the CCTA plus Heartflow pathway, uptake of Plaque Analysis and new products, automation of production steps and staffing as key factors. It also flags seasonality, particularly in the second half of the year. Plaque Tracker, which would enable longitudinal plaque analysis across sequential scans, is anticipated for 2027. These are company expectations, not completed events.